Articles from N-Power Medicine

N-Power Medicine, a company transforming oncology drug development, and New York Cancer & Blood Specialists (NYCBS), one of the nation’s largest independent community oncology practices and a longtime leader in clinical research, today announced a strategic partnership to accelerate the generation of N-Power’s Prospective External Control Arms (ProECAs). This novel approach is designed to reduce the size of oncology clinical trials and bring new therapies to patients years sooner. As part of the partnership, NYCBS will participate in the N-Power Network and offer ProECA programs to its patients, beginning in non-small cell lung cancer (NSCLC).

N-Power Medicine, a company reinventing oncology drug development and community cancer patient care, today announced the close of a $32 million Series B financing round to fuel the company’s next phase of growth – expanding its community oncology network, deepening pharma partnerships and continued investment in product development.

N-Power Medicine, a company revolutionizing oncology drug development, and AdventHealth, a faith-based health system focused on whole-person care, today announced a strategic collaboration to make clinical research more accessible for people receiving cancer care in their communities.

N-Power Medicine, a company revolutionizing oncology drug development, and VieCure, a leader in AI-powered oncology intelligence, today announced a strategic partnership to bring N-Power Medicine’s proprietary Kaleido Registry™ to the VieCure network. Through this collaboration, VieCure’s community oncology practices will gain access to both VieCure’s Halo Intelligence Platform and N-Power’s next-generation infrastructure, including its always-on Prospective External Control Arm (ProECA) platform. This model enables more community oncology practices to incorporate cutting-edge research into patient treatment plans while delivering precision medicine insights directly at the point of care.

N-Power Medicine, a company reimagining oncology drug development, today announced the launch of the industry’s first Prospective External Control Arm (ProECA) platform for pharmaceutical and biotechnology partners. Designed to reduce reliance on traditional randomized clinical trials, this groundbreaking model aims to cut patient enrollment requirements by up to 50 percent, shorten trial timelines by 6-12 months, and save tens to hundreds of millions of dollars per development program, while expanding opportunities for more patients to participate in cancer research.

N-Power Medicine, a company leading the reinvention of the clinical trial process, today announced the acquisition of Syapse Holdings Inc. (“Syapse”), a pioneer in precision medicine solutions for community cancer centers. The integration of Syapse into N-Power Medicine incorporates Syapse’s extensive network of community-based health systems, with more than 1,000 oncologists, its data and technology stack, and its dedicated team.

N-Power Medicine, a company reinventing the clinical trial process, is collaborating with Merck, known as MSD outside the United States and Canada, to enable a greater number of oncologists, and the patients they care for, to participate in clinical research. N-Power Medicine’s real-time registry and point-of-care platform combines technology, AI, and embedded research staff to deliver an integrated and efficient workflow for clinical research and routine patient care. Oncology practices in N-Power Medicine’s Clinical Research Network represent a new kind of clinical research site, with greater physician participation to increase access to clinical trials for eligible patients at the right time.

N-Power Medicine, a company reinventing the clinical trial process, announced the initial close of a Series B funding round, raising its total funding to date to $72 Million. The Series B round is led by Merck Global Health Innovation Fund, with participation by a US-based healthcare focused investor. The funds will support the expansion of the company’s network of oncology clinics and biopharmaceutical company collaborations leveraging N-Power’s unique platform for integrating clinical research into everyday patient care.